What Phase 3 Means: Understanding the TRIUMPH Program

The Pivotal Moment

Retatrutide has entered Phase 3 clinical development, known as the TRIUMPH program. If you have been following this molecule, Phase 3 is the stage that matters most. But what does Phase 3 actually mean, and what should we expect?

Phase 3: The Basics

Phase 3 trials are the large-scale, pivotal studies that provide the definitive evidence for or against a drug’s approval. If Phase 1 asks “is it safe enough to continue testing?” and Phase 2 asks “does it work and what’s the right dose?”, Phase 3 asks “does it work well enough and safely enough, in a large and diverse population, to justify approval?”

The key characteristics that distinguish Phase 3 from earlier phases:

Scale: Phase 2 studies typically enroll hundreds of participants. Phase 3 trials enroll thousands, sometimes tens of thousands. The larger size does two things: it gives more statistical power to confirm efficacy, and it builds a bigger safety database to catch uncommon side effects.

Diversity: Phase 3 trials are usually multinational, enrolling people from many countries, ethnic groups and age ranges, with a range of other health conditions. That means the results apply more widely than the fairly uniform groups in earlier trials.

Duration: Phase 3 obesity trials usually last 68-72 weeks or longer, compared with 48 weeks for retatrutide’s Phase 2. The longer treatment period captures the whole course of weight loss and gives fuller safety data.

Rigor: Phase 2 trials are carefully designed, but Phase 3 protocols are drawn up in close consultation with regulators and are monitored and audited even more closely.

What TRIUMPH Is Designed to Answer

The TRIUMPH program includes these pivotal trials, among others:

TRIUMPH-1: Obesity

The primary question: Does retatrutide produce clinically meaningful, statistically significant weight loss in a large, diverse population of adults with obesity?

Specific questions include:

• Is the ~22-24% weight loss from Phase 2 reproducible at scale?
• What is the weight loss at 80 weeks (longer than Phase 2’s 48 weeks)?
• What proportion of participants achieve the ≥5%, ≥10%, ≥15%, and ≥20% thresholds?
• Are the results consistent across demographic subgroups (age, sex, race, BMI category)?
• What is the full safety profile in a large population?

TRIUMPH-2: Obesity/Overweight With Type 2 Diabetes

The primary question: Does retatrutide produce clinically meaningful weight loss in adults with obesity or overweight (BMI ≥27) who also have type 2 diabetes?

TRIUMPH-2 includes a nested OSA basket evaluating changes in the apnea-hypopnea index. Doses are 4 mg, 9 mg, and 12 mg in 1,152 participants. Specific questions include:

• Is the weight loss meaningful in people with diabetes, where obesity drugs usually show smaller results?
• Does weight loss translate into OSA improvement (AHI reduction) in the nested basket?
• What are the secondary glycemic effects (HbA1c, fasting glucose)?
• How does the safety profile compare to Phase 2, particularly regarding hypoglycemia?

What Success Looks Like

For the FDA to approve retatrutide for obesity, the trial needs to show:

• Statistically significant weight loss versus placebo
• At least 5% mean weight loss (retatrutide far exceeds this based on Phase 2)
• An acceptable safety profile where benefits clearly outweigh risks
• Consistent results across the pre-specified primary and key secondary endpoints

For type 2 diabetes approval:

• Statistically significant HbA1c reduction versus placebo
• Acceptable safety, including low hypoglycemia rates
• Favorable benefit-risk assessment

Based on the Phase 2 data, clearing the efficacy bar should be easy if results point even roughly the same way. The main uncertainty is safety: whether the larger Phase 3 database will turn up any uncommon side effects that Phase 2 missed.

Common Misconceptions About Phase 3

”Phase 3 is just a formality after strong Phase 2 results”

This is incorrect. Approximately 50-60% of drugs that enter Phase 3 eventually receive FDA approval. The failure rate is high because Phase 3 can show weaker efficacy, unexpected safety signals or manufacturing problems that did not appear in earlier phases.

”Phase 2 results predict Phase 3 results exactly”

Phase 3 effect sizes are often modestly smaller than Phase 2 for several reasons: larger and more diverse populations, more conservative trial designs, and the statistical phenomenon of regression to the mean. However, this is not always the case. TRIUMPH-4, the first Phase 3 readout (December 2025), actually exceeded Phase 2: the 12 mg group achieved 28.7% mean weight loss at 68 weeks in 445 participants with obesity and knee osteoarthritis, compared to 24.2% at 48 weeks in Phase 2. The longer treatment (68 vs. 48 weeks) and the refined five-step dose escalation protocol probably helped. Phase 3 also revealed a new safety signal, dysesthesia in 20.9% of the 12 mg group, showing that larger trials can uncover side effects that did not stand out earlier.

”Phase 3 results will be available quickly”

Phase 3 obesity trials take years from the first enrollment to the final results. The timeline covers enrollment (which can take 12-18 months for large global trials), treatment (68-72 weeks), data collection, analysis and reporting. It takes patience.

What to Watch For

As TRIUMPH results emerge, focus on:

1. Primary endpoint: The mean weight loss (obesity) or HbA1c reduction (diabetes) versus placebo. This is the result that matters most for regulatory approval.

2. Responder rates: What proportion of participants achieved clinically meaningful thresholds? Consistent high response rates would confirm the Phase 2 pattern.

3. Safety database: The adverse event profile across thousands of participants, particularly any events not observed in Phase 2.

4. Discontinuation rates: What proportion of participants stopped treatment due to adverse events? If Phase 3 dose-escalation protocols improve on Phase 2 tolerability, this would be encouraging.

5. Subgroup analyses: Were the results consistent across age, sex, race, and baseline BMI? Inconsistencies could limit the drug’s applicability.

6. Weight trajectory: Did weight loss continue beyond the 48-week Phase 2 timepoint? If so, what was the maximum effect and when was it reached?

The Road Ahead

Phase 3 is the most expensive and slowest phase of drug development. Eli Lilly is putting substantial resources into the TRIUMPH program, and the first result has justified that spending. TRIUMPH-4 results, announced in December 2025, confirmed and exceeded Phase 2 efficacy expectations.

TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRANSCEND-T2D-1 and TRANSCEND-T2D-2 all reported in 2026, filling in the picture for the core obesity and diabetes populations that regulatory submissions rest on. Eli Lilly says it plans to file for approval no later than the first quarter of 2027; by our estimate, an FDA decision could come in late 2027 with priority review or around the first quarter of 2028 with standard review. Trials still running include TRIUMPH-5, against tirzepatide, and the TRIUMPH-Outcomes cardiovascular trial.